Nordson Corporation (NDSN) SEC Filings & Earnings Calls
EquiReason read 13 Nordson Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — Nordson completed acquisition of Contrinex for ~$168M enterprise value, expanding industrial sensing and automation portfolio. Contrinex generates ~$50M annual revenue. Acquisition.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
- Market cap
- 17.8B
- P/E TTM
- 32.3
- Dividend yield
- 1.0%
- 52-week
- —
- Next earnings
- 8 Dec, in 45 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 20268-K · 7.01, 8.01Nordson completed acquisition of Contrinex for ~$168M enterprise value, expanding industrial sensing and automation portfolio. Contrinex generates ~$50M annual revenue. Acquisition aligns with Nordson Ascend Strategy for top-tier growth.acquisitionopen
Figures in the filing · each found in the filing text
| annual revenue · Contrinex | $50M |
Risks flagged
Integration risk of Contrinex into Nordson's operations and culture.
“Acquisition integration may pose operational and cultural challenges.”
20 Aug 202610-QNordson reported Q3 FY2026 results with revenue +10.3% YoY, EPS +23% YoY, and strong ATS segment growth.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2026 | $818M | +10% y/y |
| Net income · Q3-2026 | $153M | +22% y/y |
| Diluted earnings per share · Q3-2026 | $2.73 | +23% y/y |
| Gross margin % · Q3-2026 | 55.5% | |
| Operating cash flow · 9M-2026 | $570M | +11% y/y |
| Segment EBITDA - ATS · Advanced Technology Solutions · Q3-2026 | $66M | +58% y/y |
| Segment EBITDA - IPS · Industrial Precision Solutions · Q3-2026 | $130M | -0% y/y |
| Segment EBITDA - MFS · Medical and Fluid Solutions · Q3-2026 | $88M | +6% y/y |
Risks flagged
Unrealized loss on minority investment
“Unrealized loss of $14,892 for the three months ended July 31, 2026 was included in Other income (expense) - net.”
Foreign currency exposure
“Foreign currency losses of $2,023 for three months ended July 31, 2026.”
19 Aug 20268-K · 2.02, 7.01Sales $818M (+10% y/y); Earnings per diluted share $2.73 (+23% y/y); Adjusted earnings per diluted share $3.25 (+19% y/y); Guidance: Sales guidance raised to $3,035-$3,075M; adjusted EPS to $11.80-$12.00earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2026 | $818M | +10% y/y |
| Earnings per diluted share · Q3-2026 | $2.73 | +23% y/y |
| Adjusted earnings per diluted share · Q3-2026 | $3.25 | +19% y/y |
| EBITDA · Q3-2026 | $262M | +10% y/y |
| Industrial Precision Solutions sales · Industrial Precision Solutions · Q3-2026 | $367M | +5% y/y |
| Medical and Fluid Solutions sales · Medical and Fluid Solutions · Q3-2026 | $231M | +5% y/y |
| Advanced Technology Solutions sales · Advanced Technology Solutions · Q3-2026 | $220M | +28% y/y |
Guidance
Sales guidance raised to $3,035-$3,075M; adjusted EPS to $11.80-$12.00
Full year guidance raised based on strong backlog (+35% YoY) and order entry momentum; all segments performing above expectations.
3 Jun 20268-K · 2.03Took on a material direct financial obligation, increasing leverageopen
Risks flagged
Increased leverage and short-term debt exposure; potential refinancing risk if CP market tightens.
“maximum aggregate amount outstanding at any time of $1.2 billion” · word for word
21 May 202610-QNordson reported Q2 FY2026 revenue of $740.8M (+8.5% YoY) and operating margin expansion of ~190bps, with all segments growing.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q2-2026 | $741M | +9% y/y |
| Sales · H1-2026 | $1.41B | +9% y/y |
| Net income · Q2-2026 | $117M | +4% y/y |
| Net income · H1-2026 | $251M | +21% y/y |
| Operating cash flow · H1-2026 | $321M | +15% y/y |
| Free cash flow · H1-2026 | $293M | +22% y/y |
| Segment EBITDA - IPS · Industrial Precision Solutions · Q2-2026 | $124M | +9% y/y |
| Segment EBITDA - MFS · Medical and Fluid Solutions · Q2-2026 | $79M | +4% y/y |
| Segment EBITDA - ATS · Advanced Technology Solutions · Q2-2026 | $48M | +22% y/y |
| Diluted EPS · Q2-2026 | $2.09 | +6% y/y |
Risks flagged
Pension settlement charge
“Pension settlement charge $24,049”
Derivative losses
“Foreign currency forward contracts loss $12,657 (Q2)”
20 May 20268-K · 2.02, 7.01Sales $741M (+8% y/y); Earnings per diluted share $2.09 (+6% y/y); Adjusted earnings per diluted share $2.86 (+18% y/y); Guidance: FY sales guidance raised to $2.93-3.01B; FY adjusted EPS guidance raised to $11.30-11.80.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q2-2026 | $741M | +8% y/y |
| Earnings per diluted share · Q2-2026 | $2.09 | +6% y/y |
| Adjusted earnings per diluted share · Q2-2026 | $2.86 | +18% y/y |
| EBITDA · Q2-2026 | $235M | +8% y/y |
| Industrial Precision Solutions sales · Industrial Precision Solutions · Q2-2026 | $350M | +10% y/y |
| Medical and Fluid Solutions sales · Medical and Fluid Solutions · Q2-2026 | $213M | +5% y/y |
| Advanced Technology Solutions sales · Advanced Technology Solutions · Q2-2026 | $178M | +10% y/y |
Guidance
FY sales guidance raised to $2.93-3.01B; FY adjusted EPS guidance raised to $11.30-11.80.
Company raised full-year guidance citing robust order entry and backlog growth across all segments. Q3 guidance also provided with sales $760-790M and adj. EPS $2.95-3.15.
Risks flagged
One-time pension settlement charge and non-cash loss on minority investments impacted GAAP earnings.
“Second quarter 2026 earnings included a one-time, non-cash settlement charge to annuitize about 30% of the U.S. pension obligation and a non-cash loss on minority investments recognized during the quarter.” · word for word
19 Feb 202610-QNordson reported strong Q1 FY2026 results with sales up 8.8% YoY, net income up 40.9%, and diluted EPS up 44.2%, driven by strong ATS segment growth and an unrealized gain on a minority investment.open
Figures in the filing · each found in the filing text
| Sales · Q1-2026 | $669M | +9% y/y |
| Net income · Q1-2026 | $133M | +41% y/y |
| Diluted earnings per share · Q1-2026 | $2.38 | +44% y/y |
| Gross margin · Q1-2026 | 54.7% | |
| Operating profit · Q1-2026 | $166M | +18% y/y |
| Operating cash flow · Q1-2026 | $140M | -12% y/y |
| IPS segment sales · Industrial Precision Solutions · Q1-2026 | $327M | +9% y/y |
| MFS segment sales · Medical and Fluid Solutions · Q1-2026 | $193M | -0% y/y |
| ATS segment sales · Advanced Technology Solutions · Q1-2026 | $149M | +23% y/y |
| IPS segment EBITDA · Industrial Precision Solutions · Q1-2026 | $110M | -2% y/y |
Risks flagged
Tariff and Trade Policy Risk
“The impact of changes in trade policies, tariffs, and other import/export regulations of the United States and other nations could negatively impact our cash flow from operations and liquidity in future periods.” · word for word
Foreign Exchange Risk
“We are subject to market risk arising from exchange rate movements between the dates foreign currency transactions occur and the dates they are settled.” · word for word
Geopolitical Risk
“the possible effects of events beyond our control, such as political unrest, including the conflicts in Europe and the Middle East, acts of terror, natural disasters and pandemics.” · word for word
18 Feb 20268-K · 2.02, 7.01Sales $669M (+9% y/y); Adjusted earnings per diluted share $2.37 (+15% y/y); EBITDA $203M (+8% y/y); Guidance: Full-year sales guidance raised to $2,860-$2,980M; adjusted EPS guidance raised to $11.00-$11.60.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q1-2026 | $669M | +9% y/y |
| Adjusted earnings per diluted share · Q1-2026 | $2.37 | +15% y/y |
| EBITDA · Q1-2026 | $203M | +8% y/y |
| Backlog growth · Q1-2026 | 4.0% |
Guidance
Full-year sales guidance raised to $2,860-$2,980M; adjusted EPS guidance raised to $11.00-$11.60.
Strong Q1 beat and raised full-year guidance driven by broad-based demand, semiconductor recovery, and growing backlog.
Risks flagged
Exposure to semiconductor cyclicality, though currently positive.
“Advanced Technology Solutions segment driven by semiconductor recovery.”
Foreign exchange risk, as favorable currency impact noted.
“Favorable currency translation impact of 4% in Q1.”
2 Feb 20268-K · 1.01, 2.03Nordson entered an amended and restated credit agreement with Wells Fargo and other lenders, increasing leverage capacity. No dollar amount stated; material financial obligation created.open
Risks flagged
Increased debt obligation may raise financial leverage.
“Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement.” · word for word
16 Jan 2026DEF 14ANordson filed its definitive proxy statement for the 2026 Annual Meeting, disclosing executive compensation details, governance practices, and shareholder proposals.open
Figures in the filing · each found in the filing text
| Sales · FY2025 | $2.80B | +4% y/y |
| EBITDA · FY2025 | $900M | |
| Operating Profit · FY2025 | $712M | |
| Dividends Paid · FY2025 | $179M | |
| Net Income · FY2025 | $484M | |
| Free Cash Flow · FY2025 | $661M | |
| Adjusted Earnings Per Share · FY2025 | $10.24 | |
| Gross Margin · FY2025 | 55.0% | |
| Free Cash Flow Conversion · FY2025 | 136.0% | |
| Total Shareholder Return (10 Year) · FY2025 | 226.0% |
17 Dec 202510-KSales $2.79B (+4% y/y); Net income $484M (+4% y/y); Operating cash flow $719Mopen
Figures in the filing · each found in the filing text
| Sales · FY2025 | $2.79B | +4% y/y |
| Net income · FY2025 | $484M | +4% y/y |
| Operating cash flow · FY2025 | $719M | |
| Free cash flow · FY2025 | $661M | |
| IPS segment sales · Industrial Precision Solutions · FY2025 | $1.33B | -5% y/y |
| MFS segment sales · Medical and Fluid Solutions · FY2025 | $835M | +20% y/y |
| ATS segment sales · Advanced Technology Solutions · FY2025 | $625M | +5% y/y |
| Americas sales · Americas · FY2025 | $1.21B | +2% y/y |
| Europe sales · Europe · FY2025 | $722M | -1% y/y |
| Asia Pacific sales · Asia Pacific · FY2025 | $864M | +10% y/y |
Risks flagged
Organic sales decline in IPS segment
“The IPS organic sales decrease of 5.1 percent was driven by declines in polymer processing and industrial coatings product lines.” · word for word
Tariff and trade policy exposure
“The impact of changes in trade policies, tariffs, and other import/export regulations of the United States and other nations could negatively impact our cash flow from operations and liquidity in future periods.” · word for word
10 Dec 20258-K · 2.02, 7.01Sales $752M (+1% y/y); Earnings per diluted share $2.69; Adjusted earnings per diluted share $3.03 (+9% y/y); Guidance: FY2026 sales $2,830-2,950M, adjusted EPS $10.80-11.50earningsopen
Figures in the filing · each found in the filing text
| Sales · Q4-2025 | $752M | +1% y/y |
| Earnings per diluted share · Q4-2025 | $2.69 | |
| Adjusted earnings per diluted share · Q4-2025 | $3.03 | +9% y/y |
| Sales · FY2025 | $2.80B | +4% y/y |
| Earnings per diluted share · FY2025 | $8.51 | |
| Adjusted earnings per diluted share · FY2025 | $10.24 | +5% y/y |
| EBITDA · Q4-2025 | $256M | +6% y/y |
| EBITDA · FY2025 | $900M | |
| Free cash flow · FY2025 | $661M | |
| Backlog · FY2025 | $600M | +5% y/y |
Guidance
FY2026 sales $2,830-2,950M, adjusted EPS $10.80-11.50
FY2026 guidance implies continued growth with adjusted EPS up 5-12% from FY2025; backlog up 5% provides visibility.
Risks flagged
Organic sales decline in Q4 and full year, with weakness in polymer processing and test/inspection systems.
“organic sales decrease of 1% in Q4; 3% decrease in organic volume for full year.”
FY2026 guidance midpoint implies modest growth, with first quarter sales forecasted lower sequentially.
“FY2026 sales range $2,830-2,950M vs FY2025 $2.8B; Q1 FY2026 sales forecast $630-670M vs Q4 FY2025 $752M.”
Nordson Corporation — questions
- What did Nordson Corporation file recently?
- 13 SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — Nordson completed acquisition of Contrinex for ~$168M enterprise value, expanding industrial sensing and automation portfolio. Contrinex generates ~$50M annual revenue. Acquisition aligns with Nordson Ascend Strategy for top-tier growth.
Every figure on this page comes from Nordson Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.